The Carmat company, which produces and markets an artificial heart, in difficulty for several years, on Friday announced a risk cessation risk since the end of June 2025 and the launch of a donation campaign for the continuation of its activities. “Despite all its efforts, in a very degraded financing environment,” the company will be “in a state of cessation of payments at the end of June if it cannot, then, to obtain an additional cash of at least 3.5 million euros,” he said in a press release. In more general terms, it estimates its financing needs at 12 months of around 35 million euros, including around 20 million by the end of December 2025.
Created in 2008, the company offers an “artificial heart” that aims to completely replace a heart, but to provide assistance waiting for a human heart available for transplantation. It has gone through difficult periods for several years.
An online platform “open to all”
While continuing his efforts to raise funds, in particular through capital increases, Carmat announced on Friday the launch of a donation campaign through a particular online platform to continue its activities beyond June. This donation campaign “open to all” must allow “individuals and companies that are sensitive to their project and wish to contribute to Carmat’s sustainability, to do so.”
“Today we call the generosity of each one to allow Carmat to continue saving lives,” said Stéphane Piat, CEO of Carmat, quoted in the press release.
Source: BFM TV
